Research programme: engineered protease therapeutics - Catalyst Biosciences/MedImmune

Drug Profile

Research programme: engineered protease therapeutics - Catalyst Biosciences/MedImmune

Latest Information Update: 02 Jun 2016

Price : $50

At a glance

  • Originator Catalyst Biosciences; MedImmune
  • Developer Catalyst Biosciences
  • Class Enzymes
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 02 Jun 2016 Engineered proteases research programme is still in early research for inflammation and autoimmune disorders
  • 09 Mar 2016 Catalyst Biosciences has patent protection for engineered proteases in USA and other countries (Catalyst Biosciences 10-K, March 2016)
  • 09 Mar 2016 Catalyst Biosciences has patent pending for engineered proteases in USA and other countries (Catalyst Biosciences 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top